Purine Supplementation in Patients With AICA-Ribosiduria

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age3+
SponsorCentre Hospitalier Universitaire de Saint Etienne

About this trial

AICA-Ribosiduria due to ATIC deficiency is a rare genetic metabolic disease that affects less than 10 patients (PMID: 32557644). It results in severe polyhandicap linked to neurodevelopmental disorders, visual impairment, growth retardation, severe spinal deformities and scoliosis, and often early-onset epilepsy. The disease is caused by dysfunction of the ATIC enzyme, which is involved in de novo purine biosynthesis. A recent study (PMID: 38244287) reported a decrease in disease biomarkers in a single patient after 3 months on a purine-rich diet, which persisted for at least 1 year. The investigators propose to replicate this study on several patients to investigate the potential of this treatment for this severe orphan disease.

Eligibility criteria

Qualifiers

Individual affected by AICA-ribosiduria due to ATIC deficiency

Disqualifiers

None

Trial design

Treatments tested in this trial

  • purine-rich diet

Treatment groups

10 Participants
are divided into 1 treatment group

Sponsors and collaborators

Centre Hospitalier Universitaire de Saint Etienne

Lead sponsor

University Hospital of Saint-Etienne

Collaborator